2018 was a big year for those trying to raise awareness of NASH, as well as those developing treatments and diagnostic methods. The first International NASH Day was held, a day of action with events in over a dozen cities on four continents.
2019 is already looking to be a major year for progress in the fight against NASH. Recently, Goldman Sachs declared that 2019 will be “The Year of NASH” based on the fact that several BioTech companies are expected to release late-stage trial results of promising treatments.
As such, we can expect to see a lot more media coverage of the disease and the work being done to combat it. CNBC released an in-depth article that is extremely informative and well worth reading. One interesting statistic is just how many drugs are in development right now.
Industry experts estimate the global market for these new drugs is $35 billion. Several drugs are in late-stage testing, and dozens more are in the global pipeline. BioMedtracker, a product from business intelligence firm Informa, counts 55 NASH drugs in clinical trials: 19 at Phase 1, 33 at Phase 2 and four at Phase 3.
As we usher in the New Year tonight, we can look forward with anticipation to the positive developments in the battle against NASH in the year to come.